Thus, Fallhi-Sachani and coworkers have used live-cell imaging, single-cell analysis, and molecular profiling to demonstrate that exposure of melanoma cells to RAF/MEK inhibitors elicits a heterogeneous response in which some cells die, some arrest, and the remaining progressively adapt to drug [32]. This evidence concerns the gene RAF1 and melanoma.